Comera Life Sciences Holdings, Inc.
NASDAQ Global MarketTotal Valuation
Comera Life Sciences Holdings, Inc. carries a market capitalization of 6,148.00, placing it among publicly traded companies globally. Its enterprise value stands at -1.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6,148.00 |
| Enterprise Value | -1.60M |
Share Statistics
Comera Life Sciences Holdings, Inc. currently has 30.74M shares outstanding.
| Shares Outstanding | 30.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Comera Life Sciences Holdings, Inc. maintains a current ratio of 0.90, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -4.07, indicating conservative leverage, while an interest coverage ratio of -359.32 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.90 |
| Quick Ratio | 0.64 |
| Debt / Equity | -4.07 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -359.32 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -224.98 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Comera Life Sciences Holdings, Inc.'s stock has declined approximately -52.40327% over the past 52 weeks. The 50-day moving average sits at - -, while the 200-day moving average is - -.
| Beta (5Y) | N/A |
| 52-Week Price Change | -52.40327% |
| 50-Day Moving Average | - - |
| 200-Day Moving Average | - - |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -9.05M, while operating income came in at -9.15M.
| Revenue | 1.00M |
| Gross Profit | 735,520.00 |
| Operating Income | -9.15M |
| Pretax Income | -9.01M |
| Net Income | -9.01M |
| EBITDA | -9.05M |
| EBIT | -9.15M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Comera Life Sciences Holdings, Inc. holds 1.77M in cash and equivalents against 171,596.00 in total debt, resulting in a net debt position of -1.77M. Total book value stands at -40.95M, with working capital of -301,923.00 providing operational flexibility.
| Cash & Cash Equivalents | 1.77M |
| Total Debt | 171,596.00 |
| Net Debt | -1.77M |
| Equity (Book Value) | -40.95M |
| Book Value Per Share | N/A |
| Working Capital | -301,923.00 |
Cash Flow
Comera Life Sciences Holdings, Inc. produced -6.66M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.66M |
| Capital Expenditures | -94,009.00 |
| Free Cash Flow | -6.76M |
| FCF Per Share | N/A |
Margins
Comera Life Sciences Holdings, Inc. operates with a gross margin of 73.52, reflecting its pricing power and cost economics. The operating margin of -914.32 and net profit margin of -900.56 provide insight into operational efficiency.
| Gross Margin | 73.52 |
| Operating Margin | -914.32 |
| Pretax Margin | -900.56 |
| Profit Margin | -900.56 |
| EBITDA Margin | -904.34 |
Scores
Comera Life Sciences Holdings, Inc. posts an Altman Z-Score of -28.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -28.28 |